| Target Professions: | DO, MD, Nurse Practitioner, Physician Associate/Assistant, Pharmacist |
| Target Specialties: | Nephrology, Family Medicine, Pharmacy |
| Credits Available: | 4.75 hours of AMA PRA Category 1 Credit™; ABIM MOC |
Welcome to our comprehensive learning program on screening, diagnosing, and managing IgA nephropathy (IgAN). This program aims to provide you with a deep understanding of screening techniques, referral procedures, treatment selection, drug distribution and safety and monitoring requirements in IgAN management. Furthermore, this activity encourages care coordination between interdisciplinary team members to improve the co-management of patients with IgAN.
Please answer the following questions to assess your knowledge on identifying, treating, and taking a collaborative approach to managing patients with IgAN.
This self-study module discusses the importance of screening high-risk individuals for IgAN, its diagnosis, and the importance of effective communication between nephrologists and primary care providers.
This program discusses currently approved treatment options, emerging data, and optimal disease management practices for patients with IgAN.
This module will cover the unique requirements for access to FDA-approved therapies for IgAN such as specialty pharmacies and therapy-specific REMS programs. As well as address identifying educational opportunities and building a professional network to increase referrals.
Please answer the following questions to assess the knowledge you have gained in identifying and managing IgAN using a collaborative approach to improve outcomes for patients with IgAN.
This discussion will help learners gain an understanding of the importance of screening patients for IgAN and making early diagnosis. Furthermore, this discussion aims to familiarize learners with recent guideline updates and the most recent therapies available for the management of IgAN.
This patient case challenge features a 28-year-old Japanese man who has hypertension but is otherwise asymptomatic. The patient case activity discusses screening individuals for IgA nephropathy and referring them to a nephrologist.
This patient case challenge features a 33-year-old woman with IgAN and progressive proteinuria who experiences a decline in kidney function despite treatment with angiotensin receptor blocker (ARB) and the SGLT2 inhibitor dapagliflozin.
Considering the information reviewed and discussed during this program, please share an action plan that you will implement to improve screening, diagnosis, and management for your patients with IgA nephropathy.
This discussion will focus on managing a patient with IgAN. The purpose of the discussion will be to identify a management strategy and how to co-manage the patient within a multidisciplinary team, including monitoring potential treatment-related adverse events and disease progression.
